Concizumab

CHEMBL4297730 Phase 4 승인됨 Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

An antibody therapy designed to inhibit a protein called tissue factor pathway inhibitor (TFPI), which helps restore normal clotting in patients with hemophilia. It is being studied as a subcutaneous preventive treatment to reduce bleeding episodes.

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

An antibody therapy designed to inhibit a protein called tissue factor pathway inhibitor (TFPI), which helps restore normal clotting in patients with hemophilia. It is being studied as a subcutaneous preventive treatment to reduce bleeding episodes.

Yes, Concizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297730. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.